WATERTOWN, Mass., Sept. 10 /PRNewswire/ -- Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
"We appreciate the opportunity to share some of the results from our work with this very powerful and ground-breaking chemistry platform," stated Mr. Guy Macdonald, President and CEO of Tetraphase Pharmaceuticals. "This enabling chemistry technology dramatically expands the chemical diversity of tetracyclines and is highly versatile, providing compounds with possibilities for IV and oral dosing routes and activity against multiple drug-resistant strains."
The oral presentation will be given in Hall B at the Moscone Center, in the session entitled "New Protein Synthesis Inhibitors: Oxazolidinones, Pleuromutilins and Tetracyclines", as follows:
September 14(th) (9:00 a.m. - 9:15 a.m., Poster Session 142)
The posters will be presented in Hall B at the Moscone Center, in the session entitled "New Protein Synthesis Inhibitors: Oxazolidinones, Pleuromutilins and Tetracyclines" as follows:
September 14(th) (11:15 a.m. - 1:15 p.m., Poster Session 166)
Copies of the oral presentation and the posters will be available at ICAAC and on the Tetraphase website (www.tphase.com) following ICAAC.
About Tetraphase Pharmaceuticals Inc.
Tetraphase Pharmaceuticals is capitalizing on breakthrough synthetic chemistry technology for drug discovery and development based on a process developed by world-leading organic chemist Dr. Andrew Myers of Harvard University. This enabling advance in chemistry provides the company with a broad range of commercial opportunities across a number of significant disease categories.
|SOURCE Tetraphase Pharmaceuticals Inc.|
Copyright©2009 PR Newswire.
All rights reserved